Savant Capital LLC lowered its position in shares of Allergan PLC (NYSE:AGN) by 14.8% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 1,478 shares of the company’s stock after selling 257 shares during the period. Savant Capital LLC’s holdings in Allergan PLC were worth $341,000 at the end of the most recent quarter.
A number of other hedge funds and other institutional investors have also bought and sold shares of AGN. Barnett & Company Inc. acquired a new position in Allergan PLC during the first quarter worth approximately $111,000. Livingston Group Asset Management CO operating as Southport Capital Management acquired a new position in Allergan PLC during the second quarter worth approximately $125,000. Trust Co. of Vermont increased its position in Allergan PLC by 19.5% in the second quarter. Trust Co. of Vermont now owns 545 shares of the company’s stock worth $126,000 after buying an additional 89 shares during the period. Ropes Wealth Advisors LLC increased its position in Allergan PLC by 13.2% in the first quarter. Ropes Wealth Advisors LLC now owns 497 shares of the company’s stock worth $133,000 after buying an additional 58 shares during the period. Finally, Integrated Investment Consultants LLC increased its position in shares of Allergan PLC by 35.2% in the second quarter. Integrated Investment Consultants LLC now owns 592 shares of the company’s stock worth $137,000 after buying an additional 154 shares during the last quarter. 85.19% of the stock is currently owned by institutional investors and hedge funds.
Allergan PLC (NYSE:AGN) traded up 0.72% during trading on Thursday, hitting $237.41. 2,347,453 shares of the company traded hands. The firm has a market cap of $94.00 billion, a price-to-earnings ratio of 22.60 and a beta of 0.81. Allergan PLC has a 52-week low of $195.50 and a 52-week high of $322.68. The company’s 50-day moving average is $240.82 and its 200 day moving average is $239.60.
Allergan PLC (NYSE:AGN) last announced its quarterly earnings results on Monday, August 8th. The company reported $3.35 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $3.34 by $0.01. The company had revenue of $3.68 billion for the quarter, compared to analyst estimates of $4.10 billion. Allergan PLC had a net margin of 28.06% and a return on equity of 7.67%. The firm’s revenue was up 1.0% on a year-over-year basis. During the same period in the prior year, the firm posted $4.41 earnings per share. On average, equities analysts anticipate that Allergan PLC will post $14.00 earnings per share for the current year.
A number of brokerages have recently issued reports on AGN. Piper Jaffray Cos. reaffirmed a “hold” rating and issued a $236.00 price objective on shares of Allergan PLC in a research report on Saturday, June 18th. Vetr downgraded shares of Allergan PLC from a “strong-buy” rating to a “buy” rating and set a $283.05 price objective on the stock. in a research report on Monday, August 8th. RBC Capital Markets reaffirmed an “outperform” rating and issued a $300.00 price objective (down previously from $307.00) on shares of Allergan PLC in a research report on Wednesday, August 10th. Leerink Swann set a $294.00 price objective on shares of Allergan PLC and gave the stock a “buy” rating in a research report on Monday, August 8th. Finally, JPMorgan Chase & Co. set a $325.00 price objective on shares of Allergan PLC and gave the stock a “buy” rating in a research report on Friday, August 5th. Six equities research analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has assigned a strong buy rating to the stock. The stock currently has an average rating of “Buy” and an average price target of $302.52.
About Allergan PLC
Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.
Want to see what other hedge funds are holding AGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Allergan PLC (NYSE:AGN).
Receive News & Ratings for Allergan PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan PLC and related companies with MarketBeat.com's FREE daily email newsletter.